For Biopharma, There May Be Only One Race To Watch In 2020
Senate Majority Leader McConnell is the one constant keeping drug price controls from gaining any legislative traction.
You may also be interested in...
In interview with the Pink Sheet, Jim Greenwood also worries about President Trump promoting drug pricing policies that could hinder innovation.
Medicaid’s pharmacy director says the Biogen Alzheimer’s drug is ‘currently a covered outpatient drug.’ As the payer of last resort, Medicaid could find itself significantly impacted by a Medicare national coverage decision.
A review of drugs and supplemental uses since the project’s inception shows roughly one-third of the products reviewed have been NMEs.